PhoenixBio Co., Ltd.
Research PhoenixBio Co., Ltd. (6190.T) on Bullrun: market cap JPY 1.25B, P/E 83.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6190.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 1.25B
- P/E83.2
- Financial periodFY2026
- RevenueJPY 1.57B
- Revenue growth1.6%
- Net incomeJPY 125.23M
- Free cash flowJPY 54.20M
- Gross margin76.7%
Valuation Snapshot
latest market cap is JPY 1.25B; P/E is 83.2.
Peer valuation comparison
Latest P/E is 83.2x versus a Healthcare sector median of 21.8x (281.7% above).
Latest P/E is 83.2x versus a Japan median of 14.28x (482.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 1.57B | JPY 125.23M | JPY 54.20M | 76.7% | 30.81 | JPY 1.15B | JPY 486.64M | JPY 1.55B |
| FY2025 | JPY 1.54B | -JPY 448.93M | -JPY 105.32M | 72.5% | -110.83 | JPY 1.15B | JPY 565.36M | JPY 1.37B |
| FY2024 | JPY 1.72B | JPY 26.38M | -JPY 118.08M | 69.7% | 6.98 | JPY 1.38B | JPY 723.93M | JPY 1.80B |
| FY2023 | JPY 2.12B | JPY 493.33M | JPY 265.12M | 73.3% | 97.29 | JPY 1.56B | JPY 1.13B | JPY 1.51B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 1.25B | 83.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract testing services for pharmaceutical development in Japan, the United States, Europe, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver; and PXB-cells, a human hepatocyte for studies which require the use of primary human hepatocytes, such as drug metabolism, enzyme induction/inhibition, safety assessment, transporter evaluation, anti-HBV therapeutics efficacy testing, and other studies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PhoenixBio Co., Ltd.'s market cap?
PhoenixBio Co., Ltd.'s market capitalization is JPY 1.25B.
What is PhoenixBio Co., Ltd.'s P/E ratio?
PhoenixBio Co., Ltd.'s price-to-earnings (P/E) ratio is 83.2.
What does PhoenixBio Co., Ltd. do?
PhoenixBio Co., Ltd. provides contract testing services for pharmaceutical development in Japan, the United States, Europe, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver; and PXB-cells, a human hepatocyte for studies which require the use of primary human hepatocytes, such as drug metabolism, enzyme induction/inhibition, safety assessment, transporter evaluation, anti-HBV therapeutics efficacy testing, and other studies. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications.